N-Gene Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 9

N-Gene General Information

Description

Developer of clinical-stage bio-pharmaceutical drugs designed to focus on the discovery, development, and commercialization of proprietary synthetic small molecules. The company's drugs use proprietary synthetic small molecule BGP-15 that has been found efficacious in various indications relating to adverse metabolic conditions, including type 2 diabetes mellitus by blocking JNK phosphorylation and has a new therapeutic effect via stress response modulation, enabling pharmaceutical businesses to get a series of synthetic molecules to treat the insulin-resistance syndrome, improve cancer chemotherapy and slow skin aging.

Contact Information

Website
www.ngene.us
Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 575 Madison Avenue
  • 10th Floor
  • New York, NY 10022
  • United States
+1 (212)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 575 Madison Avenue
  • 10th Floor
  • New York, NY 10022
  • United States
+1 (212)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

N-Gene Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore N-Gene‘s full profile, request access.

Request a free trial

N-Gene Patents

N-Gene Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023454616-A1 Increasing telomere length and/or suppressing telomere shortening Pending 10-Jul-2023
EP-4743072-A1 Increasing telomere length and/or suppressing telomere shortening Pending 10-Jul-2023
WO-2025014519-A1 Increasing telomere length and/or suppressing telomere shortening Inactive 10-Jul-2023
WO-2025014519-A9 Increasing telomere length and/or suppressing telomere shortening Inactive 10-Jul-2023
WO-2020044067-A1 Pharmaceutical combination to modify the effect of beta-receptor blockers and reduce side effects Inactive 30-Aug-2018 A61K31/4545
To view N-Gene’s complete patent history, request access »

N-Gene Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

N-Gene Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore N-Gene‘s full profile, request access.

Request a free trial

N-Gene FAQs

  • When was N-Gene founded?

    N-Gene was founded in 1997.

  • Where is N-Gene headquartered?

    N-Gene is headquartered in New York, NY.

  • What is the size of N-Gene?

    N-Gene has 8 total employees.

  • What industry is N-Gene in?

    N-Gene’s primary industry is Drug Discovery.

  • Is N-Gene a private or public company?

    N-Gene is a Private company.

  • What is N-Gene’s current revenue?

    The current revenue for N-Gene is .

  • How much funding has N-Gene raised over time?

    N-Gene has raised $40.1M.

  • Who are N-Gene’s investors?

    Phylaxia and Allos Therapeutics have invested in N-Gene.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process